Stockscreener 앱 받기
3.44
7.50%
0.24
전일 마감가:
$3.20
열려 있는:
$3.2
하루 거래량:
429.22K
Relative Volume:
0.66
시가총액:
$159.38M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-1.2932
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+11.69%
1개월 성능:
+18.21%
6개월 성능:
-61.04%
1년 성능:
-86.58%
1일 변동 폭
$3.18
$3.48
1주일 범위
$3.02
$3.56
52주 변동 폭
$2.235
$28.93
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
3.44 | 142.68M | 20.72M | -100.84M | -78.56M | -2.66 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Announces New Employment Inducement Grants - TradingView
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
4D Molecular Therapeutics Inc Reports Q1 2025 EPS of -$0.86, Missing Estimates; Revenue Falls Short at $14,000 - GuruFocus
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME - Nasdaq
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - Yahoo Finance
Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide - GlobeNewswire Inc.
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
4D Molecular Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Are 4D Molecular Therapeutics Inc’shares a good deal? - uspostnews.com
Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment - The Malaysian Reserve
4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA - marketscreener.com
4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema - Nasdaq
4D Molecular wins RMAT status for eye therapy (FDMT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema - Ophthalmology Times
4D Molecular Therapeutics Receives FDA RMAT Designation for 4D-150 in Diabetic Macular Edema - Nasdaq
FDA grants RMAT status to 4D Molecular’s DME therapy - Investing.com Australia
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME - GlobeNewswire
4D Molecular Therapeutics (FDMT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - Quantisnow
X-linked retinitis pigmentosa Pipeline Analysis and Clinical - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Geode Capital Management LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings - Defense World
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - The Globe and Mail
4D Molecular Therapeutics Inc [FDMT] Shares Rise 0.59 % on Wednesday - knoxdaily.com
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals Clinical Trials, Prevalence, Medication, Revenue, Statistics, Pipeline and Companies by DelveInsight - The Globe and Mail
American Express Just Delivered Fantastic News for Investors. Here's Why the Warren Buffett Stock Is a Buy Now. - The Globe and Mail
Orion Mine Finance selling at Allied Gold (AAUC) - The Globe and Mail
How should investors view 4D Molecular Therapeutics Inc (FDMT)? - uspostnews.com
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4D몰큘러 테라퓨틱스 주식 (FDMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Sep 16 '24 |
Sale |
16.33 |
500 |
8,165 |
6,781 |
| Bizily Scott | Chief Legal Officer |
Aug 19 '24 |
Option Exercise |
6.49 |
500 |
3,245 |
7,281 |
| Bizily Scott | Chief Legal Officer |
Aug 19 '24 |
Sale |
15.00 |
500 |
7,500 |
6,781 |
| Bizily Scott | Chief Legal Officer |
Jul 16 '24 |
Option Exercise |
7.60 |
1,750 |
13,295 |
8,531 |
| Bizily Scott | Chief Legal Officer |
Jul 16 '24 |
Sale |
27.11 |
1,750 |
47,442 |
6,781 |
| Bizily Scott | Chief Legal Officer |
Jul 11 '24 |
Option Exercise |
15.78 |
1,996 |
31,497 |
8,777 |
| Bizily Scott | Chief Legal Officer |
Jul 11 '24 |
Sale |
25.00 |
1,996 |
49,900 |
6,781 |
| Kirn David | Chief Executive Officer |
Jul 10 '24 |
Option Exercise |
14.55 |
12,923 |
188,077 |
1,072,076 |
| Kirn David | Chief Executive Officer |
Jul 10 '24 |
Sale |
22.49 |
12,923 |
290,598 |
1,059,153 |
| Bizily Scott | Chief Legal Officer |
Jul 01 '24 |
Option Exercise |
7.55 |
4,248 |
32,089 |
5,985 |
1.54%
7.58%
자본화:
|
볼륨(24시간):